Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:BFRGNASDAQ:CMMBNASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.71-4.9%$0.58$0.38▼$269.28$8.00M0.571.02 million shs170,912 shsBFRGBullfrog AI$1.52-7.9%$1.75$1.23▼$4.84$15.54M0.62397,043 shs238,623 shsCMMBChemomab Therapeutics$1.18-1.7%$1.28$0.87▼$2.55$22.63M0.48218,876 shs81,503 shsLSTALisata Therapeutics$2.39-3.6%$2.46$1.87▼$4.20$21.37M120,366 shs14,812 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-18.36%+39.33%+2.79%-99.05%BFRGBullfrog AI0.00%-2.37%-10.81%-12.70%-9.09%CMMBChemomab Therapeutics0.00%0.00%-12.09%-3.23%+29.03%LSTALisata Therapeutics0.00%-0.84%-6.06%+6.44%-29.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma3.3438 of 5 stars3.52.00.00.03.41.71.9BFRGBullfrog AI0.7184 of 5 stars0.05.00.00.00.02.50.0CMMBChemomab Therapeutics3.1253 of 5 stars3.55.00.00.00.01.70.6LSTALisata Therapeutics2.398 of 5 stars3.53.00.00.01.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0050,790.59% UpsideBFRGBullfrog AI 0.00N/AN/AN/ACMMBChemomab Therapeutics 3.00Buy$8.50620.34% UpsideLSTALisata Therapeutics 3.00Buy$15.00527.62% UpsideCurrent Analyst Ratings BreakdownLatest AEON, CMMB, LSTA, and BFRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ABFRGBullfrog AI$60K238.64N/AN/A$0.57 per share2.67CMMBChemomab TherapeuticsN/AN/AN/AN/A$0.72 per shareN/ALSTALisata Therapeutics$1M20.60N/AN/A$3.49 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.123.93N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)BFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%N/ACMMBChemomab Therapeutics-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)LSTALisata Therapeutics-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)Latest AEON, CMMB, LSTA, and BFRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22BFRGBullfrog AIN/A4.874.87CMMBChemomab TherapeuticsN/A5.335.33LSTALisata TherapeuticsN/A7.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%BFRGBullfrog AI0.96%CMMBChemomab Therapeutics46.05%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%BFRGBullfrog AI33.90%CMMBChemomab Therapeutics11.91%LSTALisata Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableBFRGBullfrog AI49.42 million6.22 millionNot OptionableCMMBChemomab Therapeutics2018.86 million16.61 millionNot OptionableLSTALisata Therapeutics308.62 million7.83 millionNot OptionableAEON, CMMB, LSTA, and BFRG HeadlinesRecent News About These CompaniesLisata and GATC to use AI for new opioid use disorder drugJune 18, 2025 | thepharmaletter.comLisata Therapeutics to lead development of opioid use disorder drug under expanded allianceJune 17, 2025 | proactiveinvestors.comLisata Therapeutics, Inc.: Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | finanznachrichten.deLisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC HealthJune 17, 2025 | proactiveinvestors.comLisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | globenewswire.comLisata Therapeutics to Present at the 2025 BIO International ConventionJune 11, 2025 | globenewswire.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comLisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...May 10, 2025 | finance.yahoo.comLisata Therapeutics’ Earnings Call Highlights ProgressMay 9, 2025 | tipranks.comLisata Therapeutics Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comLisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comLisata eyes key trial milestones in 2025 as certepetide development gains momentumMay 8, 2025 | proactiveinvestors.comLisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comLisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025May 1, 2025 | globenewswire.comLisata Therapeutics talks ADC breakthrough with Catalent – ICYMIApril 19, 2025 | proactiveinvestors.comLisata, Catalent partner for cancer drug researchApril 17, 2025 | uk.investing.comLisata Therapeutics signs research license with CatalentApril 15, 2025 | proactiveinvestors.comLisata Therapeutics Announces Research License with CatalentApril 15, 2025 | globenewswire.comLisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMIMarch 8, 2025 | proactiveinvestors.comLisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI TechnologyMarch 7, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEON, CMMB, LSTA, and BFRG Company DescriptionsAEON Biopharma NASDAQ:AEON$0.71 -0.04 (-4.92%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.77%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Bullfrog AI NASDAQ:BFRG$1.52 -0.13 (-7.88%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.11 (+6.91%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Chemomab Therapeutics NASDAQ:CMMB$1.18 -0.02 (-1.67%) Closing price 03:59 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Lisata Therapeutics NASDAQ:LSTA$2.39 -0.09 (-3.63%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.19 (+7.91%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
